Previous 10 | Next 10 |
ClearPoint Neuro ( NASDAQ: CLPT ) said its Swedish partner Clinical Laserthermia Systems (CLS) received the U.S. Food and Drug Administration's (FDA)510(k) clearance for its laser system to necrotize or coagulate soft tissue through interstitial irradiation or th...
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced its Swedish partner, Clinical Laserthermia Systems (CLS), ...
ClearPoint Neuro ( NASDAQ: CLPT ) said on Tuesday it had appointed Mazin Sabra as the company's Chief Operating Officer, effective October 10th. Sabra has served as Vice President of Supplier Quality Engineering for Philips since April 2021 and has also worked at...
SOLANA BEACH, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that Mazin Sabra will join the Company effective October 1...
ClearPoint Neuro ( NASDAQ: CLPT ) on Monday said it had received a U.S. FDA medical device approval for a version of its ClearPoint Neuro Navigation software. The software was given a so-called 510(k) clearance. The newer version, called 2.1, "is intended to provide st...
SOLANA BEACH, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has obtained 510(k) clearance for version 2.1 of t...
Summary Revenue growth rebounded strongly due to its acceleration in B&DD and capital equipment and software revenue. The company marks its first milestone with its FDA approval with PTC-AADC, with certainly more to come. Operating losses continue to improve from previous ...
Shares have lost 20% of their value since the initial public offering in February of last year. The company is well-positioned as a "picks and shovels" play to pharmaceutical partners addressing neurological indications. Much of the management team previously served at Philips and...
Image source: The Motley Fool. ClearPoint Neuro, Inc. (NASDAQ: CLPT) Q2 2022 Earnings Call Aug 09, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: ClearPoint Neuro, Inc. (CLPT) Q2 2022 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) Q2 2022 Earnings Conference Call August 09, 2022 04:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D’Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake S...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene the...
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at th...
SOLANA BEACH, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received 510(k) clearance for its Prism...